AD-313 is under clinical development by Apnimed and currently in Phase II for Obstructive Sleep Apnea. According to GlobalData, Phase II drugs for Obstructive Sleep Apnea have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AD-313’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AD-313 is under development for the treatment of obstructive sleep apnea. It is administered by oral route.
Apnimed discovers and develops oral pharmacologic treatments for neurologic and other related disorders. The company is investigating its lead product candidate AD109, an atomoxetine and aroxybutynin based oral solution to treat obstructive sleep apnea (OSA) and snoring. It is also evaluating AD504, an atomoxetine and trazodone formulation targeting OSA patients with disturbed sleep. The company’s science improves respiration and oxygenation during sleep and reduces the adverse health outcomes associated with OSA by targeting the neurological control and activating the upper airway dilator muscles. Apnimed is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of AD-313’s drug-specific PTSR and LoA scores, buy the report here.